Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art?

M. Mannelli; H. Dralle; J.W. M. Lenders

doi:10.1055/s-0032-1306275

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2012; 44(05): 373-378
DOI: 10.1055/s-0032-1306275

Review

Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art?

Authors

M. Mannelli

¹Department of Clinical Pathophysiology, University of Florence, Florence, Italy
H. Dralle

²Department of General, Visceral and Vascular Surgery, University of Halle-Wittemberg, Halle/Saale, Germany
J.W. M. Lenders

³Department of Medicine, Division of General Internal Medicine, Radboud Adrenal Centre, University Nijmegen Medical Centre, Nijmegen, The Netherlands

⁴Department of Medicine III, Carl Gustav Carus University Medical Centre, Dresden, Germany

Abstract

Pheochromocytoma and paraganglioma are rare tumors of sympathetic or parasympathetic origin, presenting with a highly variable clinical picture. Rarity, as well as biological, clinical, and genetic heterogeneity are barriers to initiate prospective studies that help to establish clinical guidelines. The best management of these patients relies on the experience of a multidisciplinary team. The ultimate outcome can benefit from adequate pre-surgical evaluation and treatment as well as an accurate post-surgical follow-up. Long-term follow-up is mandatory in all patients, but is particularly important in specific familial cases such as those with an SDHB mutation where the risks of recurrence are higher. The surgical approach varies depending on tumor size, location, and surgeon’s personal attitude and experience. In this paper, we summarize recommendations, based mostly on authors’ and other experts’ personal experiences, for the best possible management of patients prior, during and after surgery, as well as when pheochromocytoma is diagnosed during pregnancy.

Key words

pheochromocytoma - anesthesia - surgery - pregnancy

Full Text

References

References
1 Manger WM, Gifford Jr RW. Clinical and experimental pheochromocytoma. Cambridge, MA: Blackwell Science; 1996
2 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-675
3 Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147: 1-10
4 Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134: 315-329
5 Kuhwaide R, Lanser MJ, Fish U. Cathecolamine-secreting paragangliomas of the skull base. Skull Base Surg 1996; 6: 35-45
6 van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, Smit JW, Romijn JA, Corssmit EP. Increased Urinary Excretion of 3-methoxytyramine in Patients with Head and Neck Paragangliomas. J Clin Endocrinol Metab 2010; 95: 209-214
7 Jafri M, Maher E. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 2012; 166: 151-158
8 Manger WM. The protean manifestations of pheochromocytoma. Horm Met Res 2009; 41: 658-663
9 Liao WB, Liu CF, Chiang CW, Kung CT, Lee CW. Cardiovascular manifestations of pheochromocytoma. Am J Emerg Med 2000; 18: 622-625
10 Shao Y, Chen R, Shen ZJ, Teng Y, Huang P, Rui WB, Xie X, Zhou WL. Preoperative alpha-blockade for pheochromocytoma: is it necessary?. J Hypertens 2011; 29: 2429-2432
11 Bravo EL. Pheochromocytoma. Curr Ther endocrinol Metab 1997; 6: 195-197
12 James MFM, Cronje L. Pheochromocytoma Crisis: The use of Magnesium Sulfate. Anesth Analg 2004; 99: 680-686
13 Steinsapir J, Carr AA, Prisant LM, Bransome Jr ED. Metyrosine and pheochromocytoma. Arch Int Med 1997; 157: 901-906
14 Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with pheochromocytoma. Drug safety 2007; 30: 1031-1062
15 Desmonts JM, Marty J. Anaesthetic management of patients with phaeochromocytoma. Br J Anaesth 1984; 56: 781-789
16 Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, Schmid KW, Mann K. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg 2006; 30: 899-908
17 Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007; 92: 1217-1225
18 Burnichon N, Rohmer V, Amar L, Hermann P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F, Coupier I, Thieblot P, Lecomte P, Bertherat J, Wion-Barbot N, Murat A, Venisse A, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009; 94: 2817-2827
19 Hermsen MA, Sevilla MA, Llorente JL, Weiss MM, Grimbergen A, Allonca E, Garcia-Inclan C, Balbin M, Suarez C. Relevance of germline mutation screening in both familial and sporadic head and neck paraganglioma for early diagnosis and clinical management. Cellular Oncology 2010; 32: 275-283
20 Hu K, Persky MS. Multidisciplinary management of paragangliomas of the head and neck, part 1. Oncology 2003; 17: 983-993
21 Hu K, Persky MS. The multidisciplinary management of paragangliomas of the head and neck, part 2. Oncology 2003; 17: 1143-1153
22 Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg 2004; 91: 1259-1274
23 Toniato A, Boschin IM, Opocher G, Guolo A, Pelizzo M, Mantero F. Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment?. Surgery 2007; 141: 723-727
24 Guerrero MA, Schreinemakers JMJ, Vriens MR, Suh I, Hwang J, Shen WT, Gosnell J, Clark OH, Duh QY. Clinical spectrum of pheochromocytoma. J Am Coll Surg 2009; 209: 727-732
25 Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004; 136: 1129-1137
26 Henry JF, Sebag F, Iacobone M, Mirallie E. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World J Surg 2002; 26: 1043-1047
27 Walz MK, Peitgen K, Diesing D, Petersenn S, Janssen EO, Philipp T, Metz KA, Mann K, Schmid KW, Neumann HPH. Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasia. World J Surg 2004; 28: 1323-1329
28 Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HPH, Schmid KW, Mann K. Posterior retroperitoneoscopic adrenalectomy – results of 560 procedures in 520 patients. Surgery 2006; 140: 943-950
29 Berber E, Tellioglu G, Harvey A, Mitchell J, Milas M, Siperstein A. Comparison of laparoscopic transabdominal lateral versus posterior retroperitoneal adrenalectomy. Surgery 2009; 146: 621-626
30 Evans DB, Perrier ND. Invited commentary: on “posterior retroperitoneoscopic adrenalectomy – results of 560 procedures in 520 patients”. Surgery 2006; 140: 951-952
31 Walz MK, Peitgen K, Neumann HPH, Janssen OE, Philipp T, Mann K. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg 2002; 26: 1005-1012
32 Dralle H, Scheumann GFW, Kotzerke J, Brabant EG. Surgical management of MEN2. Rec Res Cancer Res 1992; 125: 167-195
33 Walz MK, Peitgen K, Saller B, Giebler RM, Lederbogen S, Nimtz K, Mann K, Eigler FW. Subtotal adrenalectomy by the posterior retroperitoneoscopic approach. World J Surg 1998; 22: 621-627
34 Brauckhoff M, Gimm O, Thanh PN, Bär A, Ukkat J, Brauckhoff K, Bönsch T, Dralle H. Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery 2003; 134: 1020-1028
35 Brauckhoff M, Stock K, Stock S, Lorenz K, Sekulla C, Brauckhoff K, Thanh PN, Gimm O, Spielmann RP, Dralle H. Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J Surg 2008; 32: 863-872
36 Telenius-Berg M, Ponder MA, Berg B, Ponder BAJ, Werner S. Quality of life after bilateral adrenalectomy in MEN2. Henry Ford Hosp Med J 1989; 37: 160-163
37 Machens A, Brauckhoff M, Holzhausen HJ, Thanh NP, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005; 90: 3999-4003
38 Paris J, Facon F, Thomassin JM Zanaret Cervical paragangliomas: neurovascular surgical risk and therapeutic management. Eur Arch Otohinolaryngol 2006; 263: 860-865
39 Papaspyrou K, Mann WJ, Amedee RG. Management of head and neck paragangliomas: review of 120 patients. Head Neck 2009; 31: 381-387
40 Netterville JL, Reilly KM, Robertson D, Reiber ME, Armstrong WB, Childs P. Carotid body tumors: a review of 30 patients with 46 tumors. Laryngoscope 1995; 105: 115-126
41 Linder F. Tumoren der Carotisdrüse. Langenbecks Arch Dtsch Z Chir 1953; 276: 156-161
42 Shamblin WR, ReMine WH, Sheps SG, Harrison EG. Carotid Body Tumor (Chemodectoma). Am J Surg 1971; 122: 732-739
43 Siedek V, Waggershauser T, Berghaus A, Matthias C. Intraoperative monitoring of intraarterial paraganglioma embolization by indocyaningreen fluorescence angiography. Eur Arch Otorhinolaryngol 2009; 266: 1449-1454
44 Hinermann RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck 2008; 30: 1431-1438
45 O’Riordan JA. Pheochromocytomas and anesthesia. Int Anesthesiol Clin 1997; 35: 99-127
46 Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29: 1133-1139
47 Lenders JWM. Pheochromocytoma and pregnancy: a deceptive connection. Eur J Endocrinol 2012; 166: 143-150